Perioperative Anesthetic Management for Laparoscopic Liver Resection Surgery
Conditions
Interventions
Part one:control groups:Limit fluid infusion to ensure that no more than 2.5 ml/kg of body weight per patient is infused during the induction phase of anesthesia.During surgical resection, maintain an
Part one:experimental group:During the induction phase of anesthesia, each patient will receive 5 ml/kg of crystalloid fluid supplementation to meet physiological needs. During surgery, we will perfor
Part two:G group:During surgery, we will perform goal-directed fluid therapy based on SVV (volume per beat variability). During liver resection, we will use high levels of SVV (13% to 17%) and after r
Sponsors
The First Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Ages between 18 and 75, regardless of gender; (2) Patients meeting the diagnostic criteria for hepatocellular carcinoma in China and the staging criteria of the Ministry of Health, with indications for partial hepatectomy, are scheduled for liver resection surgery; (3) Approval obtained from the hospital's ethics committee review, with patients or their relatives voluntarily signing informed consent forms; (4) First onset of illness, without prior interventions such as interventional or radiotherapy before surgery; no distant metastases, and no significant organ dysfunction; (5) Child-Pugh class A or B, ASA classification I or II, NYHA functional class I or II; (6) Expected surgery duration of 3 to 5 hours.
Exclusion criteria
Exclusion criteria: (1) Overall health is poor, with severe organic lesions, making it difficult to tolerate surgery; (2) Patients with Child-Pugh class C; (3) Patients with concomitant diseases in other organs requiring simultaneous surgical treatment; (4) Patients with severe cardiovascular or cerebrovascular diseases; (5) Patients with mental disorders; (6) Patients on prolonged use of sedative drugs; (7) Patients with a history of stroke within the last 6 months; (8) Patients with a history of alcohol abuse and chronic insomnia; (9) Those with severe coagulation disorders or severe liver and kidney dysfunction; (10) Patients refusing to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| SVV;cardiac output;mean arterial pressure;pulse rate;central venous pressure ; output per beat;cardiovascular index;liver function;kidney function;hemoglobin;lactic acid;SaO2;SvCO2;alkali residue;DO2;VO2;oxygenation index;Pv-aCO2;Intraoperative infusion volume;Norepinephrine dosage;Intraoperative urine output;Hct;Surgical time;Length of hospitalization;Total length of hospitalization; | — |
Countries
China
Contacts
Public ContactChen Hui
The First Hospital of Fujian Medical University
Outcome results
None listed